1. Home
  2. ACRS vs NMCO Comparison

ACRS vs NMCO Comparison

Compare ACRS & NMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.45

Market Cap

529.9M

Sector

Health Care

ML Signal

N/A

Logo Nuveen Municipal Credit Opportunities Fund

NMCO

Nuveen Municipal Credit Opportunities Fund

N/A

Current Price

$8.51

Market Cap

512.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
NMCO
Founded
2012
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
529.9M
512.4M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
ACRS
NMCO
Price
$3.45
$8.51
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
★ $9.82
N/A
AVG Volume (30 Days)
★ 2.6M
598.3K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 69.01
N/A
EPS
N/A
★ N/A
Revenue
★ $1,683,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.46
$8.33
52 Week High
$6.60
$11.00

Technical Indicators

Market Signals
Indicator
ACRS
NMCO
Relative Strength Index (RSI) 39.18 36.93
Support Level $3.24 $8.33
Resistance Level $4.60 $9.16
Average True Range (ATR) 0.28 0.15
MACD -0.02 -0.03
Stochastic Oscillator 17.03 15.84

Price Performance

Historical Comparison
ACRS
NMCO

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About NMCO Nuveen Municipal Credit Opportunities Fund

Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.

Share on Social Networks: